Avidity Biosciences (RNA) Operating Margin (2019 - 2025)
Historic Operating Margin for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to 1513.47%.
- Avidity Biosciences' Operating Margin rose 26874700.0% to 1513.47% in Q3 2025 from the same period last year, while for Sep 2025 it was 2934.9%, marking a year-over-year increase of 2744500.0%. This contributed to the annual value of 3477.43% for FY2024, which is 10130200.0% down from last year.
- Latest data reveals that Avidity Biosciences reported Operating Margin of 1513.47% as of Q3 2025, which was up 26874700.0% from 4448.71% recorded in Q2 2025.
- In the past 5 years, Avidity Biosciences' Operating Margin registered a high of 882.29% during Q1 2021, and its lowest value of 8360.9% during Q1 2025.
- In the last 5 years, Avidity Biosciences' Operating Margin had a median value of 2125.76% in 2022 and averaged 2731.32%.
- Examining YoY changes over the last 5 years, Avidity Biosciences' Operating Margin showed a top increase of 26874700bps in 2025 and a maximum decrease of -61823300bps in 2025.
- Over the past 5 years, Avidity Biosciences' Operating Margin (Quarter) stood at 2081.37% in 2021, then grew by 8bps to 1922.17% in 2022, then crashed by -58bps to 3043.46% in 2023, then tumbled by -34bps to 4069.63% in 2024, then soared by 63bps to 1513.47% in 2025.
- Its Operating Margin was 1513.47% in Q3 2025, compared to 4448.71% in Q2 2025 and 8360.9% in Q1 2025.